Immunohistochemistry Market Share Analysis Report, 2024-2033
The global immunohistochemistry market size was exhibited at USD 2.38 billion in 2023 and is projected to hit around USD 4.30 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2024 to 2033.
Key Takeaways:
Immunohistochemistry Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 2.53 Billion |
| Market Size by 2033 | USD 4.30 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 6.1% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Product, Application, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; PerkinElmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Abcam plc.; Agilent Technologies, Inc. |
Increasing implementation of automation and machine learning in immunohistochemistry (IHC), coupled with the introduction of technologically advanced immunohistochemistry solutions, is expected to significantly drive the market throughout the forecast period. Advancements in IHC protocols have boosted its demand to a significant level in disease diagnosis. In addition, the rise in product approvals and the launch of technologically advanced immunohistochemistry systems for disease diagnosis are further propelling the market growth.
For instance, in August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. Companies continue to launch novel products to strengthen their market position, which leads to revenue generation. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit to detect and profile biomarkers and cell populations in tissue-based research. This kit can be utilized in combination with other detection kits, expanding the multiplexing capacity of in situ hybridization and immunohistochemistry. Similarly, in March 2023, Paige announced the inclusion of artificial intelligence (AI) algorithms of Mindpeak's for immunohistochemistry biomarker quantification on the company’s platform. Mindpeak, a software company specializing in image analysis, has contributed AI algorithms designed for the analysis of immunohistochemistry slides of lung and breast tissue, which are now available on the platform. IHC technology is limited to single parametric evaluations of a samp
Newer techniques such as multiplexed IHC, however, allow multiparametric and detailed analysis from a single tissue segment by utilizing advanced methods of mass spectrometric detection. Multiplexed IHC helps address the technical challenges posed by the labeled fluorescence detection-based method, thereby spurring the market revenue. The growing elderly population in both developed and emerging nations would favorably impact the Immunohistochemistry market. The frequency of age-related disorders is expected to rise dramatically as the global geriatric population grows significantly.RT-PCR, immunohistochemistry, and an electron microscope were used to detect the virus, indicating that the effect of SARS-CoV-2 is not limited to the lungs.
Segments Insights:
Product Insights
The antibodies segment dominated the market in 2023 and accounted for the largest share of 40.96% owing to the vital usage of antibodies in disease diagnosis and drug testing. The monoclonal antibodies and antibody-related products such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominating product class in terms of usage rate. The antibodies are applied across a wide range of applications such as pathology, neuropathology, and hematopathology.
Kits are anticipated to expand at the fastest CAGR throughout the forecast period. The use of kits reduces a lot of efforts during the IHC procedure as it eliminates the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample. The compact nature and ease of use offered by the products under this segment are expected to drive the segment. IHC kits are commonly utilized in academic institutions and research laboratories that require these products in small quantities for carrying out research. Thus, rising research programs that involve the use of IHC assays are contributing to the segment growth.
Application Insights
Based on applications, the global market has been further bifurcated into diagnostics and research segments. The diagnostics application segment accounted for the largest revenue share of more than 70.0% in 2023 and is anticipated to maintain its lead over the forecast period. Immunohistochemistry (IHC) tests are widely used for the diagnosis of a wide range of chronic conditions, such as cancer, cardiovascular diseases, infectious diseases, diabetes mellitus, autoimmune diseases, and nephrological diseases. Furthermore, the growing prevalence of chronic diseases is anticipated to drive the diagnostics segment.
According to data published by the American Cancer Society, around 1.9 million new cancer cases are expected to be reported in the U.S. in 2021. With a rise in the number of cancer cases, the need for IHC techniques for rapid and efficient diagnosis is high. Thus, rising R&D activities by pharmaceutical companies for research and development of innovative drugs are anticipated to increase the demand for IHC solutions and drive the segment. For instance, in July 2021, NHS England declared a novel innovative medicine fund to accelerate the research development of new drugs.
End-use Insights
Based on end-uses, the global market has been further sub-segmented into hospitals & diagnostic laboratories, research institutes, and others. In 2023, the hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of more than 70.76% of the overall revenue. This growth was attributed to the high volume of IHC tests carried out in hospital settings. Furthermore, with the constant changes in the healthcare industry, the need for hospitals with advanced facilities has also increased. This, in turn, is also expected to increase the revenue flow in this segment.
Research institutes are expected to register a lucrative CAGR during the forecast period. This is because the technique offers several advantages over conventionally used staining techniques in pharmaceutical R&D. For instance, a human-specific IHC-approved VISTA rabbit monoclonal antibody, manufactured by Cell Signaling Technology, is available for biomedical research use. The growth can be also attributed to the wide adoption of IHC techniques in drug testing by research institutes. The technique allows the evaluation of biomarker distribution and localization and different protein expressions in varied biological tissue sections, which is conducted in research settings. Research institutes play a significant role by applying IHC techniques in drug development for the evaluation of drug efficacy tests.
Regional Insights
Based on region, the global market has been further sub-categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2023 and accounted for the largest share of more than 40.0%. of the global revenue. Key factors contributing to the regional market growth include the presence of major market players, easy availability of IHC solutions, higher adoption of technologically advanced IHC instruments, and entry of newer IHC solutions.
For instance, in June 2021, PathAI, a U.S.-based developer of AI-powered technology for pathological applications, showcased a machine learning-based quality control tool, designed for HER2 testing in breast cancer, at the American society of clinical oncology virtual scientific program 2021. Asia Pacific is expected to witness the fastest growth during the forecast period. This is primarily due to the expansion of the geographic footprint of the global players in the Asian markets. Furthermore, a large patient pool in countries such as India and China provides a large number of clinical subjects to carry out IHC R&D assays, resulting in revenue growth.
Some of the prominent players in the Immunohistochemistry market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global immunohistochemistry market.
Product
Application
End-use
By Region
Chapter 1. Immunohistochemistry Market: Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Product Segment
1.1.1.2 End-Use Segment
1.1.1.3 Application Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Immunohistochemistry Market: Executive Summary
2.1. Market Snapshot
2.2. Product and Application Snapshot
2.3. End-use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Immunohistochemistry Market: Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Emergence of multiplexed immunohistochemistry
3.4.2. Implementation of automation and machine learning in IHC
3.4.3. Increase in prevalence of cancer
3.5. Market Restraint Analysis
3.5.1. High instrument cost
3.5.2. Limitations associated with IHC technique
3.6. Industry Challenges
3.6.1. Quality assurance and standardization-related challenges
3.6.2. Limited scope for multiple evaluations
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Immunohistochemistry Market: Segment Analysis by Product, 2021 - 2033
4.1. Immunohistochemistry Market: Product Movement Analysis
4.2. Immunohistochemistry Market: Product Estimates and Forecasts, By Application (USD Million)
4.3. Antibodies
4.3.1. Antibodies Market, 2021 - 2033
4.3.2. Primary Antibodies
4.3.2.1. Primary Antibodies Market, 2021 - 2033
4.3.3. Secondary Antibodies
4.3.3.1. Secondary Antibodies Market, 2021 - 2033
4.4. Equipment
4.4.1. Equipment Market, 2021 - 2033
4.4.2. Slide Staining Systems
4.4.2.1. Slide Staining Systems Market, 2021 - 2033
4.4.3. Tissue Microarrays
4.4.3.1. Tissue Microarrays Market, 2021 - 2033
4.4.4. Tissue Processing Systems
4.4.4.1. Tissue Processing Systems Market, 2021 - 2033
4.4.5. Slide Scanners
4.4.5.1. Slide Scanners Market, 2021 - 2033
4.4.6. Others
4.4.6.1. Others Market, 2021 - 2033
4.5. Reagents
4.5.1. Reagents Market, 2021 - 2033
4.5.2. Histological Stains
4.5.2.1. Histological Stains Market, 2021 - 2033
4.5.3. Blocking Sera And Reagents
4.5.3.1. Blocking Sera and Reagents Market, 2021 - 2033
4.5.4. Chromogenic Substrates
4.5.4.1. Chromogenic Substrates Market, 2021 - 2033
4.5.5. Fixation Reagents
4.5.5.1. Fixation Reagents Market, 2021 - 2033
4.5.6. Organic Solvents
4.5.6.1. Organic Solvents Market, 2021 - 2033
4.5.7. Proteolytic Enzymes
4.5.7.1. Proteolytic Enzymes Market, 2021 - 2033
4.5.8. Diluents
4.5.8.1. Diluents Market, 2021 - 2033
4.5.9. Others
4.5.9.1. Others Market, 2021 - 2033
4.6. Kits
4.6.1. Kits Market, 2021 - 2033
Chapter 5. Immunohistochemistry Market: Segment Analysis by Application, 2021 - 2033
5.1. Immunohistochemistry Market: Application Movement Analysis
5.2. Immunohistochemistry Market: Application Estimates and Forecasts, By Application (USD Million)
5.3. Diagnostics
5.3.1. Diagnostics Market, 2021 - 2033
5.3.2. Cancer
5.3.3. Cancer Market, 2021 - 2033
5.3.4. Infectious Diseases
5.3.4.1. Infectious Diseases Market, 2021 - 2033
5.3.5. Cardiovascular Diseases
5.3.5.1. Cardiovascular Diseases Market, 2021 - 2033
5.3.6. Autoimmune Diseases
5.3.6.1. Autoimmune Diseases Market, 2021 - 2033
5.3.7. Diabetes Mellitus
5.3.7.1. Diabetes Mellitus Market, 2021 - 2033
5.3.8. Nephrological Diseases
5.3.8.1. Nephrological Diseases Market, 2021 - 2033
5.4. Research
5.4.1. Research Market, 2021 - 2033
Chapter 6. Immunohistochemistry Market: Segment Analysis by End-use, 2021 - 2033
6.1. Immunohistochemistry Market: End-use Movement Analysis
6.2. Immunohistochemistry Market: End-use Estimates and Forecasts, By Application (USD Million)
6.3. Hospitals & Diagnostic Laboratories
6.3.1. Hospitals & Diagnostic Laboratories Market, 2021 - 2033
6.4. Research Institutes
6.4.1. Research Institutes Market, 2021 - 2033
6.5. Others
6.5.1. Others Market, 2021 - 2033
Chapter 7. Immunohistochemistry Market: Regional Analysis, 2021 - 2033
7.1. Immunohistochemistry Market Share By Region, 2024 & 2033
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Immunohistochemistry Market, 2021 - 2033
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. U.S. Immunohistochemistry Market, 2021 - 2033
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Canada Immunohistochemistry Market, 2021 - 2033
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Immunohistochemistry Market, 2021 - 2033
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. Germany Immunohistochemistry Market, 2021 - 2033
7.3.4. UK
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. UK Immunohistochemistry Market, 2021 - 2033
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. France Immunohistochemistry Market, 2021 - 2033
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Italy Immunohistochemistry Market, 2021 - 2033
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Spain Immunohistochemistry Market, 2021 - 2033
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Denmark Immunohistochemistry Market, 2021 - 2033
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Sweden Immunohistochemistry Market, 2021 - 2033
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Norway Immunohistochemistry Market, 2021 - 2033
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Immunohistochemistry Market, 2021 - 2033
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. Japan Immunohistochemistry Market, 2021 - 2033
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. China Immunohistochemistry Market, 2021 - 2033
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. India Immunohistochemistry Market, 2021 - 2033
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. South Korea Immunohistochemistry Market, 2021 - 2033
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Australia Immunohistochemistry Market, 2021 - 2033
7.4.8. Thailand
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. Thailand Immunohistochemistry Market, 2021 - 2033
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Immunohistochemistry Market, 2021 - 2033
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Brazil Immunohistochemistry Market, 2021 - 2033
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Mexico Immunohistochemistry Market, 2021 - 2033
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Argentina Immunohistochemistry Market, 2021 - 2033
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Immunohistochemistry Market, 2021 - 2033
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. South Africa Immunohistochemistry Market, 2021 - 2033
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. Saudi Arabia Immunohistochemistry Market, 2021 - 2033
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. UAE Immunohistochemistry Market, 2021 - 2033
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Kuwait Immunohistochemistry Market, 2021 - 2033
Chapter 8. Competitive Landscape
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 NEW PRODUCT LAUNCH
8.2.2 PARTNERSHIPS
8.2.3 ACQUISITION
8.2.4 COLLABORATION
8.2.5 FUNDING
8.3 Key Company Market Share Analysis, 2024
8.4 Company Profiles
8.4.1 Thermo Fisher Scientific Inc.
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic Initiatives
8.4.2 F.Hoffmann-La Roche Ltd.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic Initiatives
8.4.3 Merck KGaA
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic Initiatives
8.4.4 Danaher Corporation
8.4.4.1 Company overview
8.4.4.2 Product benchmarking
8.4.4.3 Strategic Initiatives
8.4.5 Perkinelmer, Inc.
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product benchmarking
8.4.5.4 Strategic Initiatives
8.4.6 Bio-Rad Laboratories, Inc.
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic Initiatives
8.4.7 Cell Signaling Technology Inc.
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic Initiatives
8.4.8 Bio SB
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic Initiatives
8.4.9 Agilent Technologies, Inc.
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic Initiatives
8.4.10 Abcam Plc.
8.4.10.1 Company overview
8.4.10.2 Financial performance
8.4.10.3 Product benchmarking
8.4.10.4 Strategic Initiatives
Chapter 9. KOL Recommendations/ Conclusion
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers